« Back
Home /
Talacotuzumab

Talacotuzumab

Item no.	HY-P99395-10mg
Manufacturer	MedChem Express
CASRN	1826831-79-1
Amount	10 mg
Quantity options	10 mg 1 ea 1 mg 5 mg
Category	Inhibitors & Compound Libraries Small Molecules
Type	Inhibitor
Specific against	other
Purity	98.82
Dry ice	Yes
Citations	[1]S J Busfield, et al. Targeting of acute myeloid leukemia in vitro and in vivo with an anti-CD123 mAb engineered for optimal ADCC. Leukemia. 2014 Nov;28(11):2213-21.\|[2]Shereen Oon, et al. A cytotoxic anti-IL-3Rα antibody targets key cells and cytokines implicated in systemic lupus erythematosus. JCI Insight. 2016 May 5;1(6):e86131.\|[3]Erwin M Lee, et al. Efficacy of an Fc-modified anti-CD123 antibody (CSL362) combined with chemotherapy in xenograft models of acute myelogenous leukemia in immunodeficient mice. Haematologica. 2015 Jul;100(7):914-26.\|[4]L H Xie, et al. CD123 target validation and preclinical evaluation of ADCC activity of anti-CD123 antibody CSL362 in combination with NKs from AML patients in remission. Blood Cancer J. 2017 Jun 2;7(6):e567.
Smiles	[Talacotuzumab]
ECLASS 10.1	32160490
ECLASS 11.0	32160490
UNSPSC	12000000
Alias	JNJ 56022473,CSL 362
Shipping Condition	Dry ice
Available
Manufacturer - Type	Inhibitory Antibodies
Manufacturer - Applications	Cancer-programmed cell death
Manufacturer - Targets	Interleukin Related
Shipping Temperature	Dry Ice
Storage Conditions	Store at -80°C for 2 years
Molecular Weight	(147.42 kDa)
Product Description	Talacotuzumab (JNJ 56022473; CSL 362) is an IgG1-type fully humanized, CD123-neutralizing monoclonal antibody containing a modified Fc structure. Talacotuzumab has KDs of 0.43 nM, 188 nM, 46 nM, 16.8 nM for CD123, CD32b/c, CD16-158F, CD16-158V, respectively. Talacotuzumab inhibits IL-3 binding to CD123, antagonizing IL-3 signaling in target cells. Talacotuzumab has mutated the Fc region to increase affinity for CD16 (FcγRIIIa), thereby enhancing antibody-dependent cell-mediated cytotoxicity (ADCC). Talacotuzumab is highly effective in vivo reducing leukemic cell growth in acute myeloid leukemia (AML) xenograft mouse models[1][2][3][4].
Manufacturer - Research Area	Cancer
Solubility	H2O
Manufacturer - Pathway	Immunology/Inflammation
Clinical information	Phase 3

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Request Data Sheet

Request product datasheet

HY-P99395-10mg-safety-datasheet.pdf